logo
    • English
      • 简体中文
      • 繁體中文
  • Home
  • Articles
    • Insights
    • Client Press Releases
    • Client Coverage
  • Interviews
    • CEO Interview
    • PDAC Interview
  • Clients
    • Featured Companies
    • In-depth Analysis
  • Markets
    • Stock Tracker
    • Markets at a glance
    • Investing 101
      • Investing in Mining 101
        • Gold and Precious Metals
        • Electric and Battery Metals
        • Base Metals
        • Other Mining Subsectors
  • METALS 100
  • GCFF Event
    • Next Event
    • Past Events
  • Home
  • Genomics
Filter

Genomics

Categories

Sectors

Locations

Exchange

U.S. FDA approves AstraZeneca's immunotherapy for lung cancer, FDA批准阿斯利康制药的用于三期肺癌的免疫治疗药物Imfinzi

U.S. FDA approves AstraZeneca’s immunotherapy for lung cancer

Feb 16, 2018

Life Science

Resverlogix Corp TSX:RVX Pharmaceutical, Biotechnology, 医药,生物科技

Resverlogix Highlights Key Accomplishments and 2018 Targets

Feb 8, 2018

Life Science

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学

RepliCel CEO Provides 2018 Shareholder Update

Jan 25, 2018

Life Science

Biotech’s $20 billion Merger Monday sparks hope for more deals

Jan 22, 2018

Life Science

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学

RepliCel Life Sciences Lands Commitment for Key Investment Partnership

Jan 16, 2018

Life Science

Bioengineers mimic natural development to create complex living tissues

Dec 29, 2017

Life Science

Wuxi Nextcode Wins Scrip Award for Enabling the Use of The Genome to Make Better Medicine

Dec 5, 2017

Life Science

Everest Enters $224 Million Two-Drug China Partnership with Arena

Dec 5, 2017

Life Science

HitGen of Chengdu Forms Drug Discovery Partnership with Boehringer Ingelheim

Nov 29, 2017

Life Science

Resverlogix Corp TSX:RVX Pharmaceutical, Biotechnology, 医药,生物科技

Resverlogix Announces Participation in Upcoming Conferences

Nov 2, 2017

Life Science

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学

RepliCel Life Sciences Successfully Closes Financing

Oct 19, 2017

Life Science

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学

RepliCel Retains Hybrid Financial for Investor Relations

Sep 25, 2017

Life Science

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学

RepliCel’s Partnership Initiatives Mature into Licensing Negotiations

Sep 13, 2017

Life Science

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学

RepliCel Showcases First Fully-Functional Prototypes of its Next-Generation Dermal Injector

Sep 8, 2017

Life Science

South Korea’s EDGC and China’s GPBio Form Genomics Partnership

Aug 23, 2017

Life Science

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学

RepliCel Life Sciences Joins MedCision’s ThawSTAR® Early Adopter Program

Aug 16, 2017

Life Science

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学

Prominent Skin Aging Researcher Provides Insights into RepliCel’s Clinical Data

Aug 10, 2017

Life Science

Geneseeq Raises “Hundred of Millions of RMB” in C Round to Develop NGS

Jul 21, 2017

Life Science

  • ‹‹ Previous
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • Next ››

We connect Investors to Opportunities.

Financial Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

 
QuoteMedia logo

Head Office

  • 2209 – 1111 Alberni Street
    Vancouver, BC Canada V6E 4V2
  • Phone: (604) 488-8878
  • Fax: (604) 488-0868
  • Toll Free: 1 (866) 833-5517
  • Email: [email protected]

Shanghai Office

  • 06 - 607, 6/f. No.800 Shangcheng
    Road Pudong New District Shanghai,
    China
  • Phone: 021-68883919
  • Fax: 021-68882879
  • Email: [email protected]

Important Links

  • Privacy Policy
  • Terms of Use
  • Content Partner
  • NAI500 Investor Relations Services
  • About Us
  • Contact Us

© 2026 NAI Interactive Ltd. All Rights Reserved

gcff

logo

Website Design Vancouver by Nirvana Canada